Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Chlorprothixene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 4/20 | 1.00 |
| ▸ | DRD3 known ✓ | P35462 | 4/20 | 1.00 |
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 0.58 |
| ▸ | HTR2C known ✓ | P28335 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 4/20 | 1.00 |
| ▸ | HRH1 | P35367 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 3/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 3/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 3/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 3/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 3/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | HTR1A | P08908 | 2/20 | 1.00 |
| ▸ | HTR6 | P50406 | 2/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chlorprothixene SCHEMBL30383335 | 1.00 | LMNA (1.00) | LMNACYP3A4CYP2D6DRD2HRH1 | |
| Chlorprothixene SCHEMBL94235 | 1.00 | LMNA (1.00) | LMNACYP3A4CYP2D6DRD2HRH1 | |
| Chlorprothixene SCHEMBL29626798 | 1.00 | LMNA (1.00) | LMNACYP3A4CYP2D6DRD2HRH1 | |
| Chlorprothixene SCHEMBL94236 | 1.00 | LMNA (1.00) | LMNACYP3A4CYP2D6DRD2HRH1 | |
| Chlorprothixene SCHEMBL24133 | 1.00 | LMNA (1.00) | LMNACYP3A4CYP2D6DRD2HRH1 | |
| Chlorprothixene SCHEMBL455759 | 0.99 | LMNA (1.00) | LMNACYP3A4CYP2D6DRD2HRH1 | |
| Chlorprothixene SCHEMBL29857011 | 0.99 | LMNA (1.00) | LMNACYP3A4CYP2D6DRD2HRH1 | |
| Chlorprothixene SCHEMBL455758 | 0.99 | LMNA (1.00) | LMNACYP3A4CYP2D6DRD2HRH1 | |
| Chlorprothixene SCHEMBL3491182 | 0.92 | LMNA (0.84) | LMNACYP3A4CYP2D6DRD2HRH1 | |
| Chlorprothixene SCHEMBL29462906 | 0.90 | LMNA (0.84) | LMNACYP3A4CYP2D6DRD2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3507371-B1 | COMPOSITIONS FOR TREATING DISEASES AND DISORDERS OF THE NERVOUS SYSTEM | UNIV RUTGERS (US) | 2026-01-28 | — | — | EP | claimed |
| EP-4154879-B1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NICOTINE WITHDRAWAL SYMPTOMS | KOREA INST SCI & TECH (KR) | 2025-09-10 | — | — | EP | claimed |
| EP-3946296-B9 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION | DOUGLAS PHARMACEUTICALS LTD (NZ) | 2024-12-25 | — | — | EP | claimed |
| US-20240307220-A1 | Combination Therapy to Treat Temperature Sensitive Mutant Tumors | NATIONAL INSTITUTES OF HEALTH | 2024-09-19 | — | — | US | claimed |
| EP-3946296-B1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION | DOUGLAS PHARMACEUTICALS LTD (NZ) | 2024-05-01 | — | — | EP | claimed |
| EP-3529229-B1 | POLYMORPHIC FORMS OF SODIUM BENZOATE AND USES THEREOF | SYNEURX INT TAIWAN CORP (TW) | 2024-04-17 | — | — | EP | claimed |
| WO-2022187839-A1 | COMBINATION THERAPY TO TREAT TEMPERATURE SENSTIVE MUTANT TUMORS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE INC. (US) | 2022-09-09 | — | — | WO | claimed |
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| US-12550235-B2 | — | — | 2026-02-10 | — | — | US | disclosed |
| US-12454520-B2 | Protein degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2025-10-28 | — | — | US | disclosed |
| US-20250276066-A1 | METHODS, COMPOSITIONS AND COMPOUNDS FOR TREATING AGE-RELATED DISEASES AND CONDITIONS | GERO PTE LTD (SG) | 2025-09-04 | — | — | US | disclosed |
| US-12403177-B2 | Silk-based product formulations and methods of use | COCOON BIOTECH INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250262268-A1 | Methods and Compositions for Inhibiting Viral Infection | NEW YORK UNIVERSITY | 2025-08-21 | — | — | US | disclosed |
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | Didenko, Kirill (US) | 2025-07-03 | — | — | US | disclosed |
| US-20220330396-A1 | MICROWAVE HEATING UNIT AND METHOD | JT INTERNATIONAL SA (CH) | 2022-10-13 | — | — | US | disclosed |
| WO-2022187839-A1 | COMBINATION THERAPY TO TREAT TEMPERATURE SENSTIVE MUTANT TUMORS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE INC. (US) | 2022-09-09 | — | — | WO | disclosed |
| WO-2022173333-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED DISEASES AND CONDITIONS | GERO PTE. LTD. (SG) | 2022-08-18 | — | — | WO | disclosed |
| EP-3979865-A1 | MICROWAVE HEATING UNIT AND METHOD | NVX Labs GmbH (CH) | 2022-04-13 | — | — | EP | disclosed |
| EP-3962455-A1 | NEW PHARMACEUTICAL COMPOSITION FOR DRUG DELIVERY | Orexo AB (SE) | 2022-03-09 | — | — | EP | disclosed |
| EP-3747289-B1 | MICROWAVE HEATING UNIT AND METHOD | NVX LABS GMBH (CH) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12454520-B2 | Protein degraders and uses thereof | MDM2, CUL1, PSMG3 | DRD2 4552/4885DRD3 4576/4885HTR2A 3472/4885 |
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | ACE2, FURIN, SARS1 | DRD2 4342/4885DRD3 4575/4885HTR2A 1457/4885 |
| US-12550235-B2 | — | MTX2, CRY2, MTX1 | DRD2 4116/4885DRD3 4336/4885HTR2A 1521/4885 |
| US-20250276066-A1 | METHODS, COMPOSITIONS AND COMPOUNDS FOR TREATING AGE-RELATED DISEASES AND CONDITIONS | UPF1, NLN, BRCA1 | DRD2 4318/4885DRD3 4400/4885HTR2A 3360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.